By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Essential Therapeutics, Inc. (Merger Between Microcide Pharmaceuticals And The Althexis Company) 

1365 Main Street

Waltham  Massachusetts  02451  U.S.A.
Phone: 781-647-5554 Fax: 781-647-5552



Johnson & Johnson  Cephalosporin which is currently in pre-clinical stages - and will target Staphylococcal infections, Enterococcal infections, and Streptococcus pneumoniae infections.

Daiichi Pharmaceutical Co., Ltd.  A 3 year collaboration entered into November 1995. The focus is on compounds that would overcome the efflux pump mechanism of bacterial resistance, to be used in combination with antibiotics targeting pseudomonas.

Company News
Currently No News Articles